What Are Pricing Strategies for Ozempic And Wegovy With Potential Medicare Coverage Expansion? Senate Committee Questions Novo Nordisk
What Are Pricing Strategies for Ozempic And Wegovy With Potential Medicare Coverage Expansion? Senate Committee Questions Novo Nordisk
The Senate Committee on Health, Education, Labor, and Pensions is reportedly scrutinizing Novo Nordisk A/S (NYSE:NVO) 's pricing strategies, particularly those of its diabetes and obesity medications, Ozempic and Wegovy.
據報道，參議院衛生、教育、勞工和養老金委員會正在審查諾和諾德A/S（紐約證券交易所代碼：NVO）的定價策略，特別是其糖尿病和肥胖藥物Ozempic和Wegovy的定價策略。
Senator Bernie Sanders emphasized the necessity of reducing prices to ensure accessibility for consumers and sustainability for governments.
參議員伯尼·桑德斯強調了降低價格的必要性，以確保消費者的可及性和政府的可持續性。
Senator Sanders penned a letter to Novo Nordisk's CEO, Lars Fruergaard Jorgensen, demanding internal communications regarding the pricing discrepancies between the U.S. and other countries.
桑德斯參議員寫信給諾和諾德首席執行官拉斯·弗魯爾加德·約根森，要求就美國與其他國家之間的定價差異進行內部溝通。
The committee questioned why Wegovy, containing the same compound as Ozempic, bears a higher price tag, the New York Times noted. A response has been requested by May 8.
《紐約時報》指出，該委員會質疑爲什麼含有與Ozempic相同化合物的Wegovy的價格更高。已要求在5月8日之前作出回應。
Senator Sanders also intended to investigate Eli Lilly And Co (NYSE:LLY), the manufacturer of rival medications, Mounjaro and Zepbound, to address industry-wide pricing concerns.
桑德斯參議員還打算調查競爭對手藥物Mounjaro和Zepbound的製造商禮來公司（紐約證券交易所代碼：LLY），以解決全行業的定價問題。
With obesity affecting nearly 42% of American adults and over 11 percent with diabetes, ensuring affordability poses a significant challenge.
肥胖影響了將近42％的美國成年人，超過11％的人患有糖尿病，因此確保負擔能力是一項重大挑戰。
A recent study by the Kaiser Family Foundation (KFF) revealed that approximately 3.6 million overweight or obese patients with heart conditions covered under the U.S. Medicare program may become eligible for coverage of Wegovy.
凱撒家庭基金會（KFF）最近的一項研究表明，美國醫療保險計劃所涵蓋的約360萬超重或肥胖的心臟病患者可能有資格獲得Wegovy的保險。
The study highlights that the expanded coverage would affect Medicare beneficiaries and other insurers' coverage for individuals with heart conditions.
該研究強調，擴大承保範圍將影響醫療保險受益人和其他保險公司對心臟病患者的保險。
Currently, Medicare prescription drug plans (Part D) administered by private insurers do not cover drugs approved solely for obesity.
目前，私人保險公司管理的醫療保險處方藥計劃（D部分）不涵蓋僅批准用於肥胖症的藥物。
However, new guidance suggests that drugs approved for secondary use Medicare covers could be eligible.
但是，新的指導方針表明，獲准用於二次用途的醫療保險保險的藥物可能符合資格。
Citing the KFF study, Reuters highlights that the approval could open up Wegovy to over a quarter of the 13.7 million Medicare beneficiaries diagnosed with heart disease and obesity.
路透社援引KFF的研究強調，該批准可能會使Wegovy向被診斷患有心臟病和肥胖症的1,370萬醫療保險受益人中的超過四分之一開放。
Among these eligible patients, approximately 1.9 million also have diabetes, making them already eligible for Medicare coverage of other drugs like Novo's Ozempic.
在這些符合條件的患者中，約有190萬人還患有糖尿病，這使他們已經有資格獲得Novo的Ozempic等其他藥物的醫療保險。
Although some Part D plans have announced plans to cover Wegovy this year, broader coverage may be anticipated by 2025.
儘管一些D部分計劃已經宣佈了今年覆蓋Wegovy的計劃，但預計到2025年可能會有更廣泛的覆蓋範圍。
The extent of the drug's coverage and its impact on Medicare spending will depend on various factors. These include the number of Part D plans adding coverage, potential restrictions on use such as prior authorization, and negotiated prices paid by plans.
該藥物的承保範圍及其對醫療保險支出的影響將取決於各種因素。其中包括增加承保範圍的D部分計劃的數量、潛在的使用限制（例如事先授權）以及計劃支付的協議價格。
Despite major insurance plans covering these medications to varying extents, rising costs have led to coverage restrictions and termination, exacerbating accessibility issues.
儘管主要的保險計劃在不同程度上涵蓋了這些藥物，但成本上漲導致了承保限制和終止，加劇了可及性問題。
Medicaid and Medicare coverage disparities further compound the problem.
醫療補助和醫療保險覆蓋範圍的差異進一步加劇了這個問題。
Price Action: NVO shares are down 1.91% at $126.18 at the last check Wednesday.
價格走勢：在週三的最後一次檢查中，NVO股價下跌1.91％，至126.18美元。
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
免責聲明：此內容部分是在人工智能工具的幫助下製作的，並由Benzinga的編輯審閱和發佈。
Photos courtesy: Shutterstock
照片來源：Shutterstock
譯文內容由第三人軟體翻譯。